Innovent Biologics, SYCUME, Teprotumumab N01, IBI311, RESTORE-3, Thyroid Eye Disease, TED, Phase 3 Clinical Trial, IGF-1R Antibody, Proptosis, Ophthalmology, Autoimmune Disease

San Francisco, California, U.S., and Suzhou, China, October 8, 2026 Innovent Biologics has announced positive Phase 3 results for...